Longeveron (LGVN) announced the appointment of Nataliya Agafonova, M. D., as the Company’s Chief Medical Officer, CMO, effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron’s global clinical development and regulatory strategy for the Company’s investigational products. Dr. Agafonova joins Longeveron from Otsuka Pharmaceutical (OTSKY), where she served as Clinical Development Lead, Senior Medical Director, and Product Development Chair.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LGVN: